C WorldWide Group Holding A S reduced its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 47.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,670 shares of the specialty pharmaceutical company’s stock after selling 64,602 shares during the period. C WorldWide Group Holding A S’s holdings in Supernus Pharmaceuticals were worth $3,089,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. Meeder Asset Management Inc. raised its stake in Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 2,315 shares in the last quarter. Ameritas Investment Partners Inc. bought a new stake in Supernus Pharmaceuticals during the first quarter worth about $127,000. Fortaleza Asset Management Inc. bought a new stake in Supernus Pharmaceuticals during the first quarter worth about $160,000. State of Alaska Department of Revenue raised its stake in Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 170 shares in the last quarter. Finally, OppenheimerFunds Inc. bought a new stake in Supernus Pharmaceuticals during the first quarter worth about $205,000. 94.39% of the stock is currently owned by institutional investors.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) opened at 41.40 on Friday. Supernus Pharmaceuticals, Inc. has a 12 month low of $17.25 and a 12 month high of $44.95. The stock’s 50 day moving average price is $42.47 and its 200 day moving average price is $34.12. The firm has a market cap of $2.10 billion, a price-to-earnings ratio of 20.89 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The business had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $68.54 million. Equities research analysts predict that Supernus Pharmaceuticals, Inc. will post $1.04 earnings per share for the current fiscal year.

WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/12/c-worldwide-group-holding-a-s-has-3-09-million-position-in-supernus-pharmaceuticals-inc-nasdaqsupn.html.

A number of research firms have issued reports on SUPN. Jefferies Group LLC reaffirmed a “buy” rating and issued a $51.00 price target on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. Piper Jaffray Companies reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research report on Friday, August 4th. Cowen and Company reaffirmed a “positive” rating and issued a $50.00 price target (up previously from $40.00) on shares of Supernus Pharmaceuticals in a research report on Thursday, August 3rd. BidaskClub lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Finally, Janney Montgomery Scott began coverage on Supernus Pharmaceuticals in a research report on Friday, July 14th. They issued a “neutral” rating and a $47.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Supernus Pharmaceuticals has a consensus rating of “Buy” and an average target price of $48.43.

In related news, VP Padmanabh P. Bhatt sold 3,735 shares of the business’s stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $44.90, for a total value of $167,701.50. Following the transaction, the vice president now owns 21,209 shares in the company, valued at $952,284.10. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $34.90, for a total value of $191,950.00. Following the completion of the transaction, the vice president now owns 43,887 shares in the company, valued at approximately $1,531,656.30. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,291 shares of company stock worth $962,766. Insiders own 6.70% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.